GLUBIO THERAPEUTICS
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.
GLUBIO THERAPEUTICS
Industry:
Biotechnology Health Care Medical
Founded:
2021-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.glubiotx.com
Status:
Active
Total Funding:
72 M USD
Investors List
Qiming Venture Partners
Qiming Venture Partners investment in Series A - GluBio Therapeutics
Lilly Asia Ventures
Lilly Asia Ventures investment in Series A - GluBio Therapeutics
GL Ventures
GL Ventures investment in Series A - GluBio Therapeutics
E Fund Management Co.,LTD.
E Fund Management Co.,LTD. investment in Series A - GluBio Therapeutics
K2VC
K2VC investment in Series A - GluBio Therapeutics
Qiming Venture Partners
Qiming Venture Partners investment in Series A - GluBio Therapeutics
Kaitai Capital
Kaitai Capital investment in Series A - GluBio Therapeutics
Legend Capital
Legend Capital investment in Series A - GluBio Therapeutics
Official Site Inspections
http://www.glubiotx.com
- Host name: 172.67.176.127
- IP address: 172.67.176.127
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "GluBio Therapeutics"
GluBio Therapeutics
GluBio Therapeutics is a company dedicated to the discovery and development of innovative small molecule medicines by harnessing the power of targeted protein degradation (TPD).See details»
GluBio Therapeutics - Crunchbase Company Profile
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, …See details»
GluBio Therapeutics Inc - LinkedIn
Www.glubiotx.com External link for GluBio Therapeutics Inc. Industry Biotechnology Research Company size 11-50 employees Type Privately Held Founded 2021 ...See details»
GluBio Therapeutics - Overview, News & Similar companies
View GluBio Therapeutics (www.glubiotx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
GluBio Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Explore GluBio Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 1 news, Disease Domain:Hemic and Lymphatic Diseases, Neoplasms, Immune …See details»
GluBio Therapeutics - Craft
GluBio Therapeutics is a biotechnology company that focuses on developing targeted protein degradation (TPD) drugs. It provides a proprietary TPD discovery platform, a target validation …See details»
GluBio Therapeutics
Harnessing the power of targeted protein degradation to treat diseases in patients with unmet medical needsSee details»
GluBio Therapeutics - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»
GluBio Therapeutics - Company Profile - Tracxn
Sep 28, 2024 GluBio Therapeutics ranks 5th among 19 active competitors. 11 of its competitors are funded while 1 has exited. Overall, GluBio Therapeutics and its competitors have raised …See details»
GluBio Therapeutics - Tech Company Profile - Gaebler.com …
Aug 1, 2022 www.glubiotx.com. Email Address. Not Recorded. Company Background Information. Overview. GluBio Therapeutics focuses on molecular glue-targeted protein …See details»
GluBio Completes Series A+ Financing of $22 Million to Advance …
Aug 1, 2022 Founded in 2009, Kaitai Capital is an investment management organization that mainly engages in venture capital, private equity, and wealth management businesses.See details»
GluBio aims big as it takes capital raised to $90 million
Aug 2, 2022 GluBio Therapeutics, a Sino-American biotech developing novel targeted protein degradation (TPD) drugs, has completed a Series A+ financing of $22 million.See details»
Cision PR Newswire - Fox 8 Cleveland WJW
Aug 1, 2022 Supported by long-term investors to build leading TPD drug discovery platform and screening capabilitiesAdvancing two molecular glue degraders with best-in-class potential into …See details»
GluBio Completes Series A+ Financing of $22 Million to ... - BioSpace
GluBio Completes Series A+ Financing of $22 Million to ... - BioSpaceSee details»
Glubiotx.com - GluBio Therapeutics... Traffic, Ranking ... - HypeStat
Domain Name: GLUBIOTX.COM Registry Domain ID: 2587374634_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.domain.com Registrar URL: www.domain.com Updated Date: …See details»
GluBio Therapeutics
San Diego, California, Feb 23, 2024 – GluBio Therapeutics Inc., a clinical-stage, TPD-focused biotech company announced the successful completion of the first Safety Review Committee …See details»
GluBio Therapeutics Closes $22M Series A+ Financing - FinSMEs
Aug 1, 2022 GluBio Therapeutics, a San Diego, CA- and Shangai, China-based biotech company focused on developing novel targeted protein degradation (TPD) drugs, closed a …See details»
A Study of GLB-001 in Patients With Relapsed or Refractory Acute ...
Dec 6, 2023 [email protected] Summary: Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in …See details»
GluBio Therapeutics
GluBio has developed a robust drug discovery platform enabling the rational design and development of novel molecular glues and heterobifunctional degrader drugs across multiple …See details»
Gang Lu - GluBio Therapeutics Inc - LinkedIn
Experience: GluBio Therapeutics Inc · Education: UCLA · Location: San Diego · 500+ connections on LinkedIn. View Gang Lu’s profile on LinkedIn, a professional community of 1 …See details»